Health Tech: Forge Biologics; new insights from OSU cancer research; biomedical engineering

  • While small-cell lung cancer usually responds well to chemotherapy, it often returns in a treatment-resistant form that’s usually fatal. Researchers at The Ohio State University Comprehensive Cancer Center have identified molecular patterns that give insights into a new treatment.
  • Arch Oncology, a biotech startup in St. Louis has raised $105 million in a funding round led by Eventide Asset Management, Cowen Healthcare Investments and 3×5 Partners. The money will be used to further the development of biologic therapies for patients with tumors and hematologic malignancies.